Low Price with Good Quality Acipimox CAS#51037-30-0

Model NO.
Acipimox
Type
Pharmaceutical Intermediates
Application
Material Intermediates
CAS No.
51037-30-0
Other Names
Acipimox
Transport Package
25kgs Drum
Specification
99%purity
Trademark
lonwin
Origin
Made in China
HS Code
2933290090
Production Capacity
20000kgs
Reference Price
$ 5.40 - 45.00
Contact Us

Product Description

Quick Details
CAS No.:
51037-30-0

Other Names:
Acipimox

MF:
C6H6N2O3

EINECS No.:
256-928-3

Place of Origin:
China

Type:
Pharmaceutical Intermediates

Purity:
99

Brand Name:
Lonwinchem

Model Number:
TYA-02

Application:
Material Intermediates

Appearance:
white powder
Supply Ability
Supply Ability
1000 Kilogram/Kilograms per Month
Packaging & Delivery
Packaging Details
10g/bag 1kg/bag Two-layer packaging,out layer is PE,inner layer is foil bag,packed with carton
Port
main port in China
Picture Example:
 
 

Lead Time:
Quantity(Grams) 1 - 1000 >1000
Est. Time(days) 7 To be negotiated
 
 
Products Description
 
Product name
Acipimox
CAS
51037-30-0
Appearance
white powder
Assay
99
Storage
Cool and Protect from light
Product Paramenter
Product Name:Acipimox CAS:51037-30-0 MF:C6H6N2O3 MW:154.12 EINECS:256-928-3 Mol File:51037-30-0.mol
Melting point:177-180 °C Boiling point:539.0±45.0 °C(Predicted) Density 1.44±0.1 g/cm3(Predicted) storage temp. 2-8°C pka2.80±0.10(Predicted) Merck 14,111
 
DescriptionAcipimox is a potent long-acting antilipolytic nicotinic acid (NA) analog. Like nicotinic acid, acipimox lowers lipids effectively, but unlike nicotinic acid, acipimox is longer acting and therefore much less prone to produce free fatty acid rebounding. Acipimox is recommended as a lipid-lowering agent to treat hyperlipidemia in patients with noninsulin dependent diabetes mellitus. Acipimox is a hypolipidemic agent related to nicotinic acid with pronounced, longlasting antilipolytic activity. In addition to its lipid lowering activity, it produces a beneficial elevation of the anti-atherogenic high density lipoprotein subfraction, HDL2. UsesAntilipemic.

 

Pharmaceutical Intermediate

GOUV.NE, 2023